Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies

Click to increase image sizeClick to decrease image size

Acknowledgements

Dr. LeBlanc’s work on patients experience issues and palliative care integration in hematology is funded in part by a Scholar in Clinical Research grant from the Leukemia and Lymphoma Society.

Disclosure statement

I am currently, or have recently been a consultant for and/or received honoraria from AbbVie, Agilix, Agios/Servier, Astellas, AstraZeneca, Beigene, BlueNote, BMS/Celgene, CareVive, Flatiron, Genentech, GSK, Lilly, Meter Health, Novartis, and Pfizer. I have served on recent advisory boards for AbbVie, Agios, and BMS. I have received honoraria from AbbVie, Agios, Astellas, BMS/Celgene, and Incyte for recent speaking engagements. I have equity interest in Dosentrx. I have received recent research funding from the AbbVie, American Cancer Society, AstraZeneca, BMS, Deverra Therapeutics, Duke University, Jazz Pharmaceuticals, the Leukemia and Lymphoma Society, the National Institute of Nursing Research/National Institutes of Health, and Seattle Genetics.

Additional information

Funding

Dr. LeBlanc’s work on patients experience issues and palliative care integration in hematology is funded in part by a Scholar in Clinical Research grant from the Leukemia and Lymphoma Society.